Jacobi Capital Management’s CorMedix CRMD Stock Holding History

Jacobi Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-500	Closed	-$5K	–	1388
2021 Q1	$5K	Buy	+500	New	+$5.26K	﹤0.01%	1104

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jacobi Capital Management's CRMD Position: Q2 2021 in Review

Jacobi Capital Management sold out of CorMedix (CRMD) in Q2 2021, closing a stake of 500 shares — an estimated $5K sold.

Jacobi Capital Management first reported a position in CRMD in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 79 funds tracked by Wall St. Rank hold CRMD as of Q2 2021.

Jacobi Capital Management reported no remaining CorMedix position as of Q2 2021 after selling out during the quarter.
Jacobi Capital Management sold 500 CorMedix shares in Q2 2021, an estimated $5K.
Jacobi Capital Management first reported a position in CorMedix in Q1 2021 and held it in 1 quarter.
Jacobi Capital Management's CorMedix position peaked at $5K in Q1 2021.
79 funds tracked by Wall St. Rank held CorMedix as of Q2 2021.

Based on Jacobi Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.